MolMed S.p.A. | Mutual Funds
Mutual Funds that own MolMed S.p.A.
Oyster - Italian Value
3,179,879
0.69%
1,856,729
3.37%
03/29/2018
Allianz Azioni Italia All Stars
2,100,000
0.45%
0
0.32%
05/31/2018
AXA World Funds - Framlington Italy
1,600,000
0.35%
-400,000
0.19%
12/31/2017
AZ Multi Asset - Institutional Italy T
1,450,000
0.31%
0
0.12%
06/30/2017
Invesco Funds - Pan European Small Cap Equity Fund
1,205,648
0.26%
1,205,648
0.42%
03/29/2018
Zenit MC Pianeta Italia
902,960
0.2%
0
1.13%
07/31/2018
Challenge Funds - Italian Equity Fund
799,035
0.17%
0
0.14%
08/31/2018
700,000
0.15%
700,000
1.17%
03/29/2018
FCP OP Medical BioHe@lth-Trends
660,000
0.14%
0
0.18%
11/30/2017
Zenit Multistrategy SICAV - Stock-Picking
548,793
0.12%
0
1.1%
07/31/2018
| Address |
Via Olgettina, 58
Milan Milan 20132
Italy
|
|
Employees
|
- |
| Website |
http://www.molmed.it |
| Updated |
09/14/2018 |
| Molecular Medicine SpA is a medical biotechnology company which focuses on the research, development and clinical validation of therapies to treat cancer. The company's approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. Its pipeline includes antitumor therapeutics in clinical and preclinical development: Zalmoxis (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression. |
